|D015428||Myocardial Reperfusion Injury NIH||1.00|
|D014947||Wounds and Injuries NIH||0.18|
|D002318||Cardiovascular Diseases NIH||0.17|
There is one clinical trial.
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system. In addition, the study team will explore the association between high-sensitivity troponin I (TnI) levels and clinical characteristics, biomarkers, cardiac tests data and treatment approaches to uncover the potential mechanisms responsible for COVID-19 induced myocardial injury.
Description: Number of death during hospitalizationMeasure: Number of In-Hospital Death Time: During hospitalization, average 2-3 weeks
Description: Length of stay in the hospitalMeasure: Length of Stay Time: During hospitalization, average 2-3 weeks
Description: Successful treatment will be defined by two consecutive negative tests for COVID-19Measure: Number of Successful Treatment Time: During hospitalization, average 2-3 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports